Index

Page numbers in italics represent figures; those in bold, tables.

acid, citrate, and dextrose (ACD), 206
acid base disturbances, 139–140, 140
acidosis, 139–140, 140
    fluid selection in, 170
    metabolic, 175
    in pyloric obstruction, 175
acute immunologic reaction, 215
acute nonimmunologic reaction, 215
additives, fluid, 93–95, 93–96, 100
administration, routes of
    choosing, 63
    for enteral fluid, 35–36, 63
    esophagostomy and gastrostomy feeding tubes,
        38–39, 38–40, 63
        and fluid selection, 171
    intraosseous, 41–44, 42–44, 64
    intraperitoneal, 41, 64
    intravenous fluid, 44–64, 46, 48–62
    nasoendoscopic feeding tubes, 36, 36–38, 63
    subcutaneous, 40–41, 64
administration sets
    for blood transfusions, 160, 213
    burettes, 72, 72–73, 85–86
    clamps, 68, 70, 85
    drip chambers, 67–68, 68, 69, 85
    extension sets for, 72, 72, 85
    filters, 74–75, 75, 161, 187
    injection ports, 68, 70, 71, 71, 85
    pressure bags, 75–76, 76
    rate flow regulator system for, 74, 74
    replacement of, 81
    selecting, 67
    vented sets, 73–74
    Y-type, 75
agglutination, 199, 199
    and crossmatching, 201
    of RBCs, 163
air, and infusion pump use, 81
alkalosis, 139–140, 140
alkalosis, metabolic, 175
American Pediatric Surgical Association, 190
ammonia, in stored WB, 161
anemia
    iatrogenic, 57
    PRBCs for, 161–162
    and WB transfusion, 160
anorexia
    and acid-base balance, 140
    case studies, 29, 91
    CVP in, 123
anticoagulants, in blood processing, 205–206
antigens, 197
apheresis, platelet harvesting by, 211
arterial blood pressure, continuous monitoring of, 129
arterial catheterization, for DABP monitoring, 128, 128–129
aseptic technique
    for catheter insertion, 190
    for IV catheter placement, 136, 145
assessment, patient
    case studies, 29–31
    of dehydration, 15–16, 31
    of hydration and volume status, 17–29, 18–20, 22–27, 28
    of hypovolemia, 16–17
autoagglutination, 199
autotransfusion, 215, 216, 217, 217, 218
axillary temperature measurement, 109, 109, 110
Bair huggers, 111, 113
bandaging, for IV catheters, 136, 139, 146
bicarbonate, 140
blankets, hot water, 111, 114

© 2012 Charlotte Donohoe. Published 2012 by John Wiley & Sons, Inc.
blood
creating components of, 205–206
cryoprecipitate, 211–212
fresh frozen plasma, 208, 208–210, 209
fresh whole blood, 206–208, 207
packed red blood cells, 208, 208–210, 209
platelet concentrate, 210–211
platelet-rich plasma, 210–211
processing, 205–206
blood banks, 196
blood collection, 202
canine, 202–204, 203
feline, 204–205, 205, 206
blood components, 195, 217
blood component therapy, 195
blood donation, 196
blood donors, 196
canine, 196
determining recipient compatibility for, 201–202
feline, 196–197
prescreening, 197
blood gases, measurement of, 23, 27
blood loss
fluid selection in, 170
fluid therapy in, 25
blood pressure (BP)
decrease in, 21
direct arterial measurement of, 127–129, 128, 130
hypertension, 129
hypotension, 129
indirect measurement of, 125–127, 126, 127, 130
monitoring, 28
normal range for, 28
blood products, 156
delivery of, 74, 75
fresh frozen plasma, 157
human serum albumin, 158–160
immune response to, 163–164
packed red blood cells, 161–162
platelet products, 162–163, 163
stored plasma, 157–158
whole blood, 160–161, 161
blood transfusions
immune response to, 163–164
indications for, 212–213
monitoring of, 213–214
reactions to, 214–215
setting up for, 213
blood types, 197
canine, 163, 165, 197
feline, 164, 165, 198
identification of, 200
nomenclature for, 198
blood typing
canine, 199–200
feline, 200, 201
necessity of, 199, 217
blood typing cards, 200, 201
blood urea nitrogen (BUN), 26, 26, 202
blood volume, and pulse quality, 22
body water
and body weight, 4–5
compartments for, 3–6, 4–5, 6, 11
defined, 3
electrolytes in, 7, 7–8, 8, 12
gain and loss, 8–11
boluses, in fluid delivery, 79–80, 82
bradyarrhythmias, 8
bradycardia, 205
causes of, 116
treatment of, 116
bradypnea, 118
burettes, 72, 72–73, 85–86, 89, 92
butterfly catheters, 47, 48, 204
cage, metabolic, 131
capillary refill time (CRT), 168
cardiac output (CO), 21
case studies
depression, 91
diarrhea, 29 (see also diarrhea)
patient assessment, 29–31
catheters
daily evaluation of, 139, 146
intraosseous, 137
for PN administration
selection of, 186–187
sites and solution sets for, 187
urinary, 131
catheters, intravenous
butterfly catheters, 47, 48, 204
complications associated with, 46, 46, 135–136
central lines, 138–139, 146
embolism, 137, 146
jugular catheters, 138–139, 146
vascular inflammation and infection, 136–137
main types of, 64
materials for, 46–47
measurements for, 46
multilumen, 57–63
over-the-needle, 48–53, 48–55
selection of, 135, 145
site preparation for, 136, 145
through-the-needle, 53–54, 55–56, 56–57
central lines, 46
complications associated with, 138–139, 146
indications for, 137
maintenance of, 138, 146
placement of, 63
for TPN administration, 187
central venous catheterization, through-the-needle catheters for, 55
central venous catheters, 57, 57, 58
central venous pressure (CVP)
decreased, 123
increased, 124–125
measurement of, 54, 121, 121, 122, 125
units for measurement of, 122
cerebrospinal space, ECF in, 5
chemosis, 142–143
chloride (Cl-)
in fluid maintenance, 7, 7, 8
in gastric fluid, 169
citrate phosphate dextrose adenine (CPDA)
in blood collection systems, 205
WB stored in, 160
clamps, for fluid administration sets, 68, 70, 85
collection systems, for blood transfusion, 203, 203
colloid osmotic pressure, 9–10, 12
colloids
characteristics of, 153–154, 164
complications associated with, 142
indications for, 141–142
natural, 156, 156–164, 161–163, 165
side effects associated with, 154
synthetic, 154, 154–156, 164
for trauma patients, 174
constant rate infusion (CRI), 73, 96
continuous infusion, calculating, 96
conversions, for fluid infusions, 99, 100
crackles, 117
crossmatching, 201–202, 217
cryoprecipitate (Cryo)
derivation of, 211
indications for, 212
crystalloids, 141
characteristics of, 149–150, 164
hypertonic saline, 152, 152–153
maintenance, 151, 151–152, 164
replacement, 150, 150–151, 164
for trauma patients, 174
dehydration
causes of, 15, 16
explained, 15
hypertonic, 16
hypotonic, 16
isotonic, 16
depression, case study, 91
dextans, 155
dextrose
fluid supplemented with, 95–96
in PPN, 180
Dial-a-Flo infusion systems, 74
diarrhea, 24
and acid-base balance, 140
case studies, 29, 91
choosing fluids for, 169–171
clinical signs of, 168–169, 169
CVP in, 123
fluid selection in, 170, 171
digestion, oxidation in, 9
direct arterial blood pressure (DABP) measurement,
127–129, 128, 130, 130
disks, microwaveable, 111, 112
dog erythrocyte antigens (DEAs), 163–164, 197–198
donor recipient compatibility, determining, 201–202
Doppler method, of BP measurement, 125–126, 126,
130
dorsal pedal pulses, 23, 23
dressing, for IV catheters, 136, 139, 146
drip chambers, 67–68, 68, 69, 85
drip rate
formula for, 90
setting, 89
edema
peripheral (interstitial), 10, 143
pulmonary, 143, 144
electrocardiogram (ECG), 22, 113–114, 115,
132
electrolyte, use of term, 7
electrolytes, 23, 27
concentration of, 8
in PPN, 180
role of, 7
supplementation with, 93
embolism, IV catheters associated with, 137, 146
emergency database, 173
equations, for fluid infusions, 99, 100
esophagostomy tube, 38, 38–40, 63
extension sets, 72, 72
extracellular fluid (ICF)
body water in, 3, 4–5, 11
in eyes, 5
eye position, and hydration status, 19–20, 20
eyes, ECF in, 5
febrile (pyrexic) patients, 110–111
feeding, enteral, 184
feeding tubes, 38–39, 38–40, 63
femoral pulses, 22.23
fever, and acid-base balance, 140. See also pyrexia
filters
for IV administration sets, 74–75, 75
for PN administration, 187
for PRBC transfusions, 161
fluid choice
   and acid-base balance, 141
   alkalinizing solutions, 141
   complications associated with
      acidosis and alkalosis, 139–140, 140
      colloids, 141–142
      overadministration, 142–146, 144, 145, 146,
      146
   crystalloid solutions, 141
   glucose-containing solutions, 141
fluid loss, in hypovolemia, 16–17. See also blood loss
fluid maintenance. See also maintenance rate
   plasma protein in, 9–10
   solutes in, 10–11
fluid movement, control of, 5
fluid rate, 100. See also maintenance rate
fluids. See also colloids; crystalloids
   choosing suitable, 149, 164
   hypertonic, 11, 12
   hypotonic, 10–11, 11, 12
   isotonic, 10, 11, 12, 40, 170
fluid selection, 167, 176
   patient evaluation in, 167–168
   in pyloric obstruction, 175–176, 176
   for trauma patients, 172, 172–175
fluid therapy, ix
   complications associated with, 145
   catheter-associated, 135–139
   fluid choice, 139–145, 144, 145, 146
   overadministration, 142–146, 144, 145, 146,
   146
   goals of, 174
   maintenance phase of, 171
   monitoring of, 171
   USG in, 132
fresh frozen plasma (FFP), 156, 157, 209
   indications for, 210
   packaging of, 208, 209
   preparation of, 208–209
fresh plasma (FP), 195
fresh whole blood (FWB). See also whole blood
   compared with whole blood, 208
   components of, 206
   indications for, 207

gastrointestinal tract, fluid administration via, 35–36, 63
gastrostomy tube, 38–40, 39, 63
gel method, of blood typing, 200
guidewire, in central line placement, 63
guidewire catheters, 64

heart rate (HR)
   bradycardia, 116
   elevation of, 22

hydration, 21–22
   monitoring, 111–112, 115, 132
   tachycardia, 115–116
   thoracic auscultation of, 112, 114

hemoconcentration, 24
hemorrhage, massive, 17, 173
hetastarch, 155
hospitalization
   isotonic replacement solutions during, 171
   nutrition during, 179

hospitals
   monitoring equipment of, 168
   PN protocols of, 187–188
human serum albumin (HSA), 156
   benefits of, 158
   derivation of, 18
   test dose of, 159
   transfusion reaction to, 160

hydration, 15
   clinical assessment of
      eye position in, 19–20, 20
      heart rate in, 21–22
      mentation, 20
      mucous membrane moisture, 18–19, 19
      pulse quality, 22, 22–23, 23, 31
      quick assessment tests, 23–24
      skin turgor/skin tent, 17, 18
      vital parameters, 20–21, 31
   evaluation of, 168
   hydrostatic pressure, 149
   hypercarbia, 116
   hyperglycemia, during parenteral nutrition, 190–191
   hyperkalemia, 8
   hypernatremia, 153
   hypertension, causes of, 129
   hyperthermia, 110, 132
   hypertonic saline (HTS), 152, 152–153, 175
   hypocalcemia, 211
   hypoglycemia, 95, 191
   hypokalemia, 116
   clinical signs of, 191–192
   in GI upset, 169
   in pyloric obstruction, 175
   hypomagnesemia, 192
   hyponatremia, in pyloric obstruction, 175
   hypophosphatemia, clinical signs of, 191
   hypotension, 129
   hypothermia, 111
   hypovolemia
      CVP in, 123
      defined, 16, 31
      explained, 15
      fluid selection in, 171
      pulse quality in, 22–23
      tachycardia in, 116
   hypovolemic shock, 10
immune responses, to blood transfusion, 215
immune thrombocytopenia purpura (ITP), 211
inappetence, case study, 91
infection, PN therapy associated with, 189–190
injection ports, 68, 70, 71, 85
International System of Units, 87
interstitial fluid (ICF), 3, 4, 11. See also edema
interstitial space, crystalloids in, 149
intracellular fluid (ICF), body water in, 3, 4, 5
intravascular fluid administration, 41–44, 42–44
access sites for, 42, 42–43, 43
advantage of, 42
catheter-like devices for, 44, 44
complications associated with, 137
complication with, 42
indications for, 171
monitoring, 43–44
intraperitoneal (IP) fluid administration, 41, 64
intravascular space, 3, 5
intravascular volume, in sickness, 16
intravenous fluid administration, 44. See also catheters,
intravenous
benefit of, 45
catheters for, 46, 46–64, 48–62
determining volume for, 45
potential complications of, 45
intravenous fluid therapy, potassium supplementary
guidelines for, 176, 176
intravenous (IV) nutrition, 179. See also parenteral
nutrition
ions, 7
jugular catheters, complications associated with, 138
jugular vein
for catheter placement, 53
central line placement in, 58, 59–62
thrombosis of, 139, 146
kidneys, and acid-base balance, 140
kilogram, in fluid therapy calculations, 88
lactate, blood, 27
lactated Ringer solution (LRS), 40, 141, 150
compared with HTS, 153
for vomiting/diarrheic patients, 171
lactate levels, monitoring of, 168–169
lethargy, in case study, 29
light, reaction of drugs to, 97–98
lipids, in TPN, 181, 182, 183, 192
lock feature, for infusion pumps, 80–81
Luer adapter, 70, 71, 85
Luer lock, 71
lung sounds, moist, 117
magnesium (Mg”), in fluid maintenance, 7, 8
maintenance fluids, 171
maintenance rate, 87
calculating, 88, 88–93, 91, 92
“twice maintenance,” 90
malnutrition
physical features suggesting, 184, 186
PN in, 182
manometer, CVP measured with, 121, 121, 123, 124
mean arterial pressure (MAP), 28, 28
defined, 126
in hypotension, 129
mentation, and hydration, 20
metabolic acidosis, 175
metabolic cage, 131
metabolic water, 87
meter, in fluid therapy calculations, 88
Mik antigen, in cats, 198
millimoles per liter (mmol/L), 8
mole, in fluid therapy calculations, 88
molecular weight, 8
monitoring
during blood collection, 204
of blood transfusions, 213–214
of fluid therapy, 171
monitoring, patient, 107, 132, 133
blood pressure, 125–130, 126–128, 130, 130, 133
of body weight, 118–121, 119, 120, 133
central venous pressure, 121, 121–125, 122, 122–124, 133
heart rate, 111–116, 115, 132
respiratory rate, 116–118, 132
tachypnea, 117–118
urine output, 131–132, 133
vital signs, 107–108
mucous membranes (MMs), evaluation of, 18–19, 19, 168
multilumen catheters, 57, 57, 58
complications associated with, 138
placement of, 58–59, 59–62, 63
for TPN administration, 187
uses for, 58
multivitamins, in PPN, 180, 192
nasal discharge, serous, 143
nasoesophageal feeding tubes, 36, 63
complications associated with, 38
confirming placement of, 37
insertion of, 36–37
neoplastic disease, cachexia associated with, 185
normal saline, one-half (0.45% NaCl), 151, 152
normal saline (0.9% NaCl), 40, 141, 150, 150–151
Normosol R, 141, 150
   for trauma patients, 174
   for vomiting/diarrheic patients, 171
nutrition. See also parenteral nutrition
   enteral, 184
during hospitalization, 179
   nutritional support, 38
nutrition therapy, goal of, 188

oat bags, microwaveable, 111, 112
occlusions
   with infusion pump use, 81–82
   with syringe pumps, 84
oncotic pressure, 9–10, 12
defined, 149
   of HSA, 158

Ontario Veterinary College Teaching Hospital, 71, 80, 213
oscillometric pressure measurements, 126–127, 127, 130
osmosis, process of, 5, 6
osmotic pressure, 5–6, 6, 149
osteomyelitis, from catheter contamination, 137
overadministration of fluids, 142
chemosis, 142–143
   peripheral edema from, 143
   pleural effusion, 143–145, 144, 144, 145
   pulmonary edema in, 143
   serous nasal discharge in, 143
overload, fluid, clinical signs of, 146
overload volume, clinical signs of, 164
over-the-needle catheters, 48–53, 48–55
   placement of, 49, 49–51
   securing in place, 51–53, 52–53
   supplies for, 51, 51
oxidation, in digestion, 9
oxyglobin, 155–156

packed cell volume (PCV), 23, 24, 24–26, 25
   as guideline for PRBC transfusion, 162
posttransfusion, 214
   for posttraumatic fluid therapy, 173
   supplies for measuring, 25
   for WB transfusion, 161
packed red blood cells (PRBCs), 195
   indications for, 209–210
   packaging of feline, 208
   preparation of, 161, 208–209
   stored plasma administered with, 158
pain, in cardiovascular assessment, 115
parenteral nutrition, 179, 192
   administration of, 185–188, 188
   in advanced care setting, 181–188, 183–185, 186
   complications of, 189, 192
      hyperglycemia, 190–191
      hypoglycemia, 191
infection, 189–190
   mechanical, 189, 192
   refeeding syndrome, 191–192
   indications for, 184, 184–185, 185, 185
   partial (PPN), 179–181, 180
timely initiation of, 184
total (TPN), 181
   volumes for, 188
PENTASPAN, 154
pentastarch, 155
perfusion, fluid selection in compromised, 171
peritoneal cavity, 41
pH, changes in, 139
phlebitis
   associated with IV catheters, 137, 146
   central lines associated with, 138
physical examination
   in blood collection, 202
   BP measurement in, 28
   before fluid therapy, 167
   nutritional status in, 184, 186
   preliminary evaluation, 17
piggybacking, 71, 71
plasma, 3, 4–5, 5, 11. See also fresh frozen plasma
   composition of, 16
   platelet-rich, 195, 210
   stored, 156, 157–158
Plasma-Lyte A (PLA), 141, 150
   for trauma patients, 174
   for vomiting/diarrheic patients, 171
Plasma-Lyte 148, for trauma patients, 174
   for vomiting/diarrheic patients, 171
plasma protein, and fluid maintenance, 9–10
platelet concentrate (PC), 195
   administration of, 211, 212
   packaging of, 210
   preparation of, 211
platelet products, 162–163, 163
platelet-rich plasma (PRP), 195, 210
platelets
   indications for, 211
   preparation of products from, 210–211
pleural effusion, 143–145, 144, 144, 145
Potassium chloride, as fluid additive, 94, 94–95
potassium (K+),
   in fluid maintenance, 7, 7–8
   in gastric fluid, 169
   supplementation guidelines for, 176, 176
preload, 121
prescription, fluid therapy, 87
pressure bags, 75–76, 76
   pulmonary edema, 143, 144, 205
   pulse oximetry, 117, 118, 132
pulse quality
evaluation of, 22, 22–23, 23, 31
poor, 112
pumps, fluid infusion, 67, 76, 77. See also syringe pumps
benefits of, 76–77
calculating maintenance rate with, 89, 100
double, 76, 78
drawbacks of, 77–79
lock feature of, 80–81
maintenance of, 79–81, 86
occlusion alarms on, 77
potential complications of, 86
silence button for, 80
syringe pumps, 82, 83, 84–85
troubleshooting, 81–82
purpura, 215
pyloric obstruction, 151, 157–176, 176
pyrexia (fever), 110–111, 132
quick analysis tests (QUATS), 23
rate
for fluid delivery, 79
maintenance, 87, 88, 88–93, 91, 92
rate flow regulator, 74, 74, 92
reactions, transfusion, 214–215
red blood cells (RBCs), 197
agglutination of, 199, 199
in crossmatching, 201
refeeding syndrome, and PN, 191–192
replacement fluids, 170, 171
respiration, and maintenance of proper pH, 139–140
respiratory rate (RR)
bradypnea, 118
measurement of, 116–117
tachypnea, 117–118, 118
resting energy requirement (RER), 188
resuscitation phase, of fluid therapy, 169–170
saphenous vein, for catheter placement, 53
scales
mobile, 120
tabletop, 119, 120
walk-on, 118, 119
screening tests, for HSA donors, 158
second, in fluid therapy calculations, 88
sedation, for blood collection, 202–203
Seldinger technique, modified, 58–59, 59–62, 63
semipermeable membranes, 5, 6, 6
sepsis, physiologic changes in, 119–121
shock, hypovolemic, 10
SI units, 87
skin tent, 17
evaluation of, 168
skin turpura, evaluation of, 17, 18
small animal practices, ix
sodium (Na+) in fluid maintenance, 7, 7, 8
in gastric fluid, 169
sodium potassium pump, 7, 8
solute concentrations, 10
solute molecules, 10
sutures, defined, 5
spinal needles, as intraosseous catheters, 44, 44
starvation, stress vs. simple, 182
sterile technique
during autotransfusion, 216
in PN therapy, 189, 192
stoma care, in feeding tube maintenance, 139
stored plasma (SP), 156, 157–158
students, technician, ix
subcutaneous (SC) administration, 40–41, 64
supplements, calculations for, 100, 101
synovial joints, ECF in, 5, 6
syringe pumps (syringe drivers), 82, 83, 86
alarms for, 84, 86
setting up, 82, 84
troubleshooting, 84–85
systolic blood pressure, 126
tachycardia, 21–22, 115–116
tachypnea, 117–118, 118
technical calculations, 87, 87
for continuous infusion, 96
conversions and equations for, 99, 100
for fluid additives, 93–95, 93–96, 100
maintenance rate, 88, 88–93, 91, 92
technicians
advanced care, x
role of, ix
temperature
decreases in, 111, 112–114
inches in, 110–111
normal, 132
temperature, pulse, respiration (TPR)
in blood collection, 204, 205
and test dose for HSA, 159
thermistor, 108
thermometers, 108, 108
disposable plastic sleeves for, 108, 109
placement of, 109
“third spacing,” 120
thromboembolism, IV catheters associated with, 137, 146
thrombosis
central lines associated with, 138–139
jugular, 139, 146
jugular catheter associated with, 138
Index

thrombus formation  
with IV catheters, 46, 46
during PN administration, 186, 190

through-the-needle catheters, 53–54, 55–56, 56–57
drawing samples with, 56–57
needle guards with, 57
placement of, 53–54

total parenteral nutrition (TPN)  
adadministration of, 188
risks associated with, 187

total solids (TS), 23, 25, 25–26
decreased, 25–26
increases in, 24–25
for posttraumatic fluid therapy, 173

total volume, in fluid administration, 80
transcellular fluid compartments, 5
transducer, CVP computed with, 121, 122
transfusion medicine, 195, 198, 217. See also blood transfusions
transfusion reactions, 214–215
trauma patients, 25
eyearly evaluation of, 173
fluid choices for, 174–175
initiating fluid therapy for, 172
transport of, 173

urine, collection of, 131
urine output, monitoring, 131–132, 133
urine scald, 131
urine specific gravity (USG), 27, 27–28, 131, 132

vascular system, 16
vasculature, body water within, 5
vena cava, cranial, for catheter placement, 53, 54, 57
vented administration sets, 73–74
vital signs  
assessment of, 20–21, 31
in blood collection, 204, 205
monitoring, 107–108
with test dose for HSA, 159
vitamin imbalances, in refeeding syndrome, 192
vitamins, in PPN, 180, 181, 192
volume status, 15
volume to be infused (VTGI), 79, 100
volumetric infusion pumps, 76. See also pumps
vomiting, 24
and acid-base balance, 140
case studies, 29, 91
choosing fluids for, 169–171
clinical signs of, 168–169, 169
CVP in, 123
fluid selection in, 170, 171
hemorrhagic, 30
von Willebrand factor, 211
von Willebrand factor deficiency, 212

water. See body water
water consumption, 9
water gain, diet and, 9
water loss, 8–9
weight, body
monitoring, 118
scales for monitoring, 118–119, 119, 120
serial measurement of, 121
weight loss, 181, 183
wheeze, 117
whole blood (WB), 156, 160–161, 161
centrifugation of, 195
compared with FWB, 208
fresh, 206, 207–208
indications for, 171
for trauma patients, 175

Y-type infusion sets, 75